Belinostat

Belinostat is an intravenous histone deacetylase (HDAC) inhibitor used for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL). It works by inhibiting histone deacetylase enzymes, which regulate gene expression, thereby promoting cell cycle arrest and apoptosis in malignant cells.

Approved by the U.S. FDA in 2014, Belinostat (marketed as Beleodaq? by Spectrum Pharmaceuticals) is primarily indicated for patients who have failed prior systemic therapy for PTCL. This guide offers a detailed overview of Belinostat, its uses, dosage, side effects, interactions, and benefits to help patients and healthcare providers make informed decisions about its use.

What is Belinostat?

Belinostat is an anticancer agent belonging to the histone deacetylase (HDAC) inhibitor class. It selectively inhibits HDAC enzymes, which play a crucial role in DNA transcription and chromatin re-modeling. By increasing the acetylation of histone proteins, Belinostat reactivates tumor suppressor genes, leading to cell cycle arrest (G1/G2 phase) and apoptosis in cancer cells. It is indicated for relapsed or refractory peripheral T-cell lymphoma (PTCL) and is currently being investigated for other hematologic malignancies and solid tumors.

Uses of Belinostat

Belinostat is primarily used for:

• Peripheral T-Cell Lymphoma (PTCL): Approved for the treatment of relapsed or refractory PTCL, a rare and aggressive form of non-Hodgkin lymphoma.
• Combination Therapy: Often studied in combination with other chemotherapy agents for various cancers, although these uses are still experimental.
• Off-Label Uses: Investigated for other hematologic malignancies and solid tumors, though not yet FDA-approved for these indications.

Dosage of Belinostat

Belinostat is administered intravenously, and the dosage is tailored to the patient?s weight, condition, and treatment response.

Standard Dosage:

Adult Patients: The recommended dose is 1,000 mg/m? of body surface area, administered as a 30-minute intravenous infusion. Infusions are given once daily on Days 1-5 of a 21-day treatment cycle.

Duration of Treatment:

Treatment is continued until disease progression or unacceptable toxicity occurs.

Special Considerations:

• Dosage adjustments may be required for patients with liver or kidney impairment.
• Pretreatment with antiemetics may be recommended to prevent nausea and vomiting.

Side Effects of Belinostat

Like all chemotherapy drugs, Belinostat has side effects that range from mild to severe.

Common Side Effects:

• Fatigue
• Nausea and vomiting
• Fever
• Anemia (low red blood cell count)
• Thrombocytopenia (low platelet count)
• Neutropenia (low white blood cell count)

Severe Side Effects:

• Infections: Neutropenia can lead to life-threatening infections.
• Hepatotoxicity: Elevated liver enzymes may indicate liver damage.
• Tumor Lysis Syndrome: Rapid cancer cell destruction can lead to metabolic complications.
• Hypersensitivity Reactions: Rash, swelling, or difficulty breathing during or after infusion.

Patients should immediately report any severe or unusual symptoms to their healthcare provider.

Interaction with Other Medicines

Belinostat is metabolized primarily by the liver enzyme CYP2A, and its effectiveness and safety can be influenced by other medications.

Drug Interactions:

• CYP2A Inhibitors: Drugs like methoxsalen may increase Belinostat levels, raising the risk of toxicity.
• CYP2A Inducers: Medications such as phenobarbital can reduce the effectiveness of Belinostat by lowering its concentration in the blood.
• Anticoagulants: Increased risk of bleeding when combined with anticoagulants like warfarin.
• Other Chemotherapeutic Agents: Coadministration with other cytotoxic agents may amplify side effects like bone marrow suppression.

Alcohol:

Avoid alcohol consumption, as it may exacerbate liver toxicity. Patients should always inform their healthcare provider about all medications, supplements, or herbal products they are taking to prevent harmful interactions.

Benefits of Belinostat

• Targeted Action: Inhibits histone deacetylase enzymes, selectively targeting cancer cells while sparing normal tissues.
• Effective in PTCL: Demonstrates significant efficacy in treating relapsed or refractory peripheral T-cell lymphoma.
• Flexible Dosing: The ability to adjust doses makes it suitable for a broad range of patients, including those with mild organ impairments.
• Combination Potential: Shows promise when combined with other chemotherapeutic agents in clinical studies.
• Improved Quality of Life: Provides symptom relief and disease control in patients with aggressive cancers.

FAQs About Belinostat

• What is Belinostat used for? Belinostat is used to treat relapsed or refractory peripheral T-cell lymphoma (PTCL) in adults.
• How does Belinostat work? Belinostat inhibits histone deacetylase (HDAC) enzymes, promoting cancer cell death and slowing tumor growth.
• How is Belinostat administered? It is administered as an intravenous infusion over 30 minutes, typically once daily for five days in a 21-day cycle.
• What are the most common side effects of Belinostat? Common side effects include fatigue, nausea, anemia, and low white blood cell counts.
• Can Belinostat be used in children? The safety and efficacy of Belinostat in pediatric patients have not been established.
• Are there dietary restrictions while taking Belinostat? While no specific dietary restrictions are required, patients should maintain good hydration and avoid alcohol to reduce liver stress.
• How long does it take for Belinostat to work? The response time varies depending on the patient and disease severity. Regular monitoring is essential to assess effectiveness.
• Can I take vaccines while on Belinostat? Avoid live vaccines during treatment, as Belinostat suppresses the immune system, increasing the risk of infection.
• What should I do if I miss a dose of Belinostat? Contact your healthcare provider immediately for guidance. Missing doses can impact the treatment?s effectiveness.
• Is Belinostat safe during pregnancy or breastfeeding? Belinostat may harm an unborn baby or pass into breast milk. It is not recommended during pregnancy or breastfeeding. Discuss contraception and alternatives with your doctor.

Brand Names of Belinostat

Beleodaq? (Spectrum Pharmaceuticals)

Conclusion

Belinostat (Beleodaq?) is a histone deacetylase inhibitor indicated for relapsed or refractory peripheral T-cell lymphoma (PTCL). It induces apoptosis in cancer cells through epigenetic modulation and offers an alternative treatment for patients with limited options. Although generally well-tolerated, it carries risks of myelosuppression, infection, and hepatotoxicity, requiring close medical monitoring. When administered under expert supervision, Belinostat provides a meaningful therapeutic benefit for aggressive T-cell lymphomas.